Literature DB >> 19273113

Peroxisome proliferator-activated receptors and renal diseases.

Jing Wu1, Lihong Chen, Dongjuan Zhang, Ming Huo, Xiaoyan Zhang, Dan Pu, Youfei Guan.   

Abstract

Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily of ligand-dependent transcription factors. Three isoforms of PPAR, i.e., PPAR-a, -d, and -?, have been identified and are differentially expressed in various tissues, including the kidney. The target genes of PPARs are involved in diverse biological processes, including adipogenesis, lipid metabolism, insulin sensitivity, inflammatory response, reproduction, and cell growth and differentiation. PPARs have been reported to protect against renal injury through indirect systemic effects and/or direct renal effects in diabetic nephropathy, glomerulonephritis, renal cell carcinoma, acute renal failure and chronic renal disease. In this review, we summarize the role of the three identified PPAR isoforms, PPARa, -d, and -?, in renal physiology and discuss the renoprotective effects of PPAR ligands in various kidney diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19273113     DOI: 10.2741/3291

Source DB:  PubMed          Journal:  Front Biosci (Landmark Ed)        ISSN: 2768-6698


  19 in total

Review 1.  Potential effects of curcumin on peroxisome proliferator-activated receptor-γ in vitro and in vivo.

Authors:  Mohsen Mazidi; Ehsan Karimi; Mohsen Meydani; Majid Ghayour-Mobarhan; Gordon A Ferns
Journal:  World J Methodol       Date:  2016-03-26

2.  A mouse model of alcoholic liver fibrosis-associated acute kidney injury identifies key molecular pathways.

Authors:  Shinji Furuya; Grace A Chappell; Yasuhiro Iwata; Takeki Uehara; Yuki Kato; Hiroshi Kono; Ramon Bataller; Ivan Rusyn
Journal:  Toxicol Appl Pharmacol       Date:  2016-09-15       Impact factor: 4.219

Review 3.  [New approaches in progressive kidney diseases].

Authors:  P Boor
Journal:  Pathologe       Date:  2012-11       Impact factor: 1.011

Review 4.  Renal fibrosis: novel insights into mechanisms and therapeutic targets.

Authors:  Peter Boor; Tammo Ostendorf; Jürgen Floege
Journal:  Nat Rev Nephrol       Date:  2010-09-14       Impact factor: 28.314

5.  Thiazolidinedione-dependent activation of sphingosine kinase 1 causes an anti-fibrotic effect in renal mesangial cells.

Authors:  A Koch; A Völzke; C Wünsche; D Meyer zu Heringdorf; A Huwiler; J Pfeilschifter
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

6.  Opposite action of peroxisome proliferator-activated receptor-gamma in regulating renal inflammation: functional switch by its ligand.

Authors:  Xiaoyan Wen; Yingjian Li; Youhua Liu
Journal:  J Biol Chem       Date:  2010-07-27       Impact factor: 5.157

7.  Relationships among injury, fibrosis, and time in human kidney transplants.

Authors:  Jeffery M Venner; Konrad S Famulski; Jeff Reeve; Jessica Chang; Philip F Halloran
Journal:  JCI Insight       Date:  2016-01-21

8.  PPARα agonist fenofibrate enhances fatty acid β-oxidation and attenuates polycystic kidney and liver disease in mice.

Authors:  Ronak Lakhia; Matanel Yheskel; Andrea Flaten; Ezekiel B Quittner-Strom; William L Holland; Vishal Patel
Journal:  Am J Physiol Renal Physiol       Date:  2017-09-13

Review 9.  Crosstalk of Hyperglycemia and Dyslipidemia in Diabetic Kidney Disease.

Authors:  Wen Su; Rong Cao; Yong Cheng He; You Fei Guan; Xiong Zhong Ruan
Journal:  Kidney Dis (Basel)       Date:  2017-09-13

Review 10.  PPARs Integrate the Mammalian Clock and Energy Metabolism.

Authors:  Lihong Chen; Guangrui Yang
Journal:  PPAR Res       Date:  2014-02-19       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.